If the FDA directed that the EpiPen ANDA be resubmitted as a 505b2 NDA, I presume that Teva would have disclosed that.
Siggi Olafsson was asked about this possibility at Teva's Q3 2015 CC and answered: "...our EpiPen was 505(b)(1) application, and it doesn't automatically switch into a 505(b)(2) overnight. There's no magic that can happen down in Washington. So my assumption is, and we still think we are going for a AB rated EpiPen, that's our strategy. And until I see what I get in the Complete Response Letter, I don't think -- I can't even speculate. But our application is for AB rated, not for non-AB rated."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.